SCHEMBL467341

SCHEMBL467341

NC=CCNCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063077 0.81
SCHEMBL526332 0.78
SCHEMBL25179568 0.77 CA1 (0.35)
SCHEMBL455193 0.76
SCHEMBL866509 0.76
SCHEMBL8520637 0.76 TSHR (0.42)
SCHEMBL4786114 0.76
SCHEMBL232854 0.76
SCHEMBL29956913 0.76
SCHEMBL17667385 0.74 TSHR (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120027677-A1 Prion-specific peptoid reagents NOVARTIS AG 2012-02-02 US claimed
EP-2383281-A2 Prion-specific peptoid reagents Novartis AG (CH) 2011-11-02 EP claimed
US-6756199-B1 USED FOR THE SYNTHESIS OF BOTH PREDEFINED AND RANDOM SEQUENCE PEPTIDE NUCLEIC ACID OLIGOMERS ISIS PHARMACEUTICALS, INC. 2004-06-29 US claimed
EP-1369037-B2 Synergistic preparations based on mixtures of glycerol ether with aromatic alcohol for controlling mycobacteria SCHUELKE & MAYR GMBH (DE) 2024-07-17 EP disclosed
EP-3193941-B1 PRODRUGS COMPRISING AN AMINOALKYL GLYCINE LINKER ASCENDIS PHARMA AS (DK) 2024-05-22 EP disclosed
EP-3565573-B1 PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF UNIV CALIFORNIA (US) 2023-08-23 EP disclosed
US-11707431-B2 Dental strips for the delivery of specifically targeted antimicrobial peptides C3 JIAN, LLC (US) 2023-07-25 US disclosed
US-20230146954-A1 MICELLAR DISINFECTANTS DENT4YOU AG (CH) 2023-05-11 US disclosed
US-11633341-B2 Dental varnishes that release specifically targeted antimicrobial peptides and/or fluoride C3 JIAN, LLC (US) 2023-04-25 US disclosed
US-11555055-B2 Peptide inhibitors of insulin-degrading enzyme THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-01-17 US disclosed
EP-4110055-A1 MICELLAR DISINFECTANTS Dent4You Ag (CH) 2023-01-04 EP disclosed
EP-1369037-A1 Synergistic preparations based on mixtures of glycerol ether with aromatic alcohol for controlling mycobacteria Air Liquide Santé (International) (FR) 2003-12-10 EP disclosed
US-6608026-B1 Contacting pathogenic cells with AV peptoid which comprises amino acid sequence Ala-Val-Pro, is fewer than 20 residues in length, has molecular weight less than 1000, and interacts with Inhibitor of Apoptosis protein, to enhance apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-19 US disclosed
WO-2002016402-A2 APOPTOTIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-02-28 WO disclosed
EP-0535155-B1 LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE CHIRON CORP (US) 2002-01-30 EP disclosed
US-6075121-A HETEROPOLYMERIC PEPTOID COMPOUND CONSISTING OF 2 TO 50 N-SUBSTITUTED GLYCINES HAVING DIFFERENT ALPHA-AMINO R GROUPS; CAPABLE OF NON-NATURAL CONFIGURATIONS FOR DRUG DESIGN CHIRON CORPORATION (US) 2000-06-13 US disclosed
US-5965695-A PEPTOIDS COMPRISED OF 2-50 MONOMER UNITS INCLUDING AT LEAST 2 N-SUBSTITUTED GLYCINE RESIDUES; THE PEPTOIDS ARE CONJUGATED TO A DRUG SUCH AS AZT OR TRIMETHOPRIM, FOR INCREASED BINDING AFFINITY TO A PARTICULAR BIOLOGICAL RECEPTOR CHIRON CORPORATION (US) 1999-10-12 US disclosed
US-5811387-A ENZYME RESISTANT OLIGO- OR POLY-PEPTOID WHICH MAY SELECTIVELY BIND TO POLYPEPTIDE OR EFFECTOR MOLECULE; MIMETICS, PEPTOID LIBRARIES CHIRON CORPORATION (US) 1998-09-22 US disclosed
EP-0535155-A4 LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE BARTLETT PAUL A (US) 1994-08-17 EP disclosed
EP-0535155-A1 LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE BARTLETT, Paul A. (US) 1993-04-07 EP disclosed